Program
JNJ-95597528
A development code.
Its studies are mostly in Dermatitis, Atopic · Asthma, led by Johnson & Johnson.
Furthest: phase 2, since Nov 14, 20252 company-led studies, 2 open or runningNext primary completion: Nov 19, 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 22 open or running | phase 2since Nov 14, 2025 | Nov 14, 2025 | Nov 19, 2026phase 2 · NCT07230860 |
- Named in Johnson & Johnson’s own pipeline as
JNJ-7528
, phase 2, as of Oct 13, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 14, 2025First study: phase 2 study in Dermatitis, AtopicFirst studyNCT07230860 · 189 enrolled · United States, Argentina, Brazil and more
- Jul 31, 2026Phase 2 study in AsthmaNCT07746687 · 440 planned · United States, Argentina, China and more
Ahead
- Nov 19, 2026Primary completion: phase 2 study in Dermatitis, AtopicNCT07230860
- Sep 11, 2029Primary completion: phase 2 study in AsthmaNCT07746687
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07746687Asthma · United States, Argentina, China and more | 2 | Recruiting | Sep 11, 2029 | 440 |
| NCT07230860Dermatitis, Atopic · United States, Argentina, Brazil and more | 2 | Active, not recruiting | Nov 19, 2026 | 189 |
How it is read
Names in the registry
- “JNJ-95597528”, 2 entries
Codes read as this program: JNJ95597528.
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 1 study
- Asthma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.